Hello,
Today in healthcare news: Oscar fell in its stock-market debut, inside DispatchHealth’s latest (short!) pitch deck that it used to reach a $1.7 billion valuation, and the data is in on how vaccine work outside clinical trials.
Mario Schlosser, CEO and co-founder of Oscar speaks to guests during the TechCrunch Disrupt event in Manhattan, in New York City, NY, U.S. May 15, 2017.
Eduardo Munoz/Reuters
Eduardo Munoz/Reuters
Oscar Health, the original buzzy health-insurance startup, fell 11% in its IPO. We pored over its 215-page filing to find 4 key takeaways.
- Shares of Oscar Health, founded by Joshua Kushner and Mario Schlosser, fell 11% in the company’s stock-market debut on Wednesday.
- Its S-1 filing lays out its financials and a dual-class stock structure allowing founders to keep control.
- We pored over the insurer’s 215-page filing to find the key takeaways.
Read the full story from Shelby Livingston here>>
Nathan Hindman/DispatchHealth
We got an exclusive look at the presentation that convinced Tiger Global and Humana to invest in a startup’s bold vision to do hospitalizations at home at a $1.7 billion valuation
- At-home healthcare startup DispatchHealth said Wednesday it had raised $200 million in Series D funding.
- The round, led by Tiger Global, valued Dispatch at $1.7 billion.
- See the short pitch deck that earned the eight-year-old startup unicorn status.
Read the full story from Blake Dodge and Megan Hernbroth here>>
CHRIS JACKSON/POOL/AFP via Getty Images
The data is in: COVID-19 vaccines are proving to be crucial in curbing the pandemic by slashing infections, hospitalizations, and deaths
- The coronavirus vaccines being rolled out are really, really good.
- The first real-world data shows huge drops in transmission, infections, and hospitalizations.
- Vaccines are more than a silver lining to the pandemic - they're our way out.
Read the full story from Andrew Dunn here>>
More stories we're reading:
- Dr. Fauci has a stunningly simple way to explain how Johnson & Johnson's COVID-19 vaccine differs from Pfizer's and Moderna's shots (Insider)
- Merck is preparing to launch a new trial for a COVID-19 drug after acquiring it in 2020 (Bloomberg)
- Johnson & Johnson's CEO doesn't want to go back to 'business as usual' after the pandemic and hopes public-private partnerships among pharmaceutical firms continue (Insider)
- Amazon Care's medical provider has filed paperwork in 17 states beyond Washington (Stat News)
- Biden is picking up the work on cancer he started as Obama's VP. His science advisor nominee Eric Lander is expected to lead the effort. (Insider)
- Lydia
Read the original article on Business Insider
Dit artikel is oorspronkelijk verschenen op z24.nl